LTR PHARMA LIMITED — Director's Dealing 2025

Nov 19, 2025

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity LTR Pharma Limited ABN 42 103 087 449

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Lee Rodne
Date of last notice	9 December 2024

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

	Direct or indirect interest	Direct or indirect interest	Direct or indirect interest		Direct	Direct
	Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.				Not applicable
	Date of change				19 November 2025
	No. of securities held prior to change				Direct1,129,641 Fully Paid Ordinary Shares1,000,000 Unlisted Options exercisable at$0.22 per option expiring 31 October 2028100,000 Unlisted Options exercisable at $2.52per option expiring 2 December 2028Indirect46,373,750 Fully Paid Ordinary Shares held byLTR Medical Pty Ltd982,143 Fully Paid Ordinary Shares held byLTR Consulting Pty Ltd4,188,000 Fully Paid Ordinary Shares held byTrexapharm Inc
					1,129,641 Fully Pa1000000 Unliste	id Ordinary Sharesd Otions exercisab
					,,$0.22 per option ex	ppiring 31 October 202

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Class		Unlisted Options
Number acquired		2,000,000
Number disposed		Not applicable
Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation		Nil consideration
No. of securities held after change		Direct1,129,641 Fully Paid Ordinary Shares1,000,000 Unlisted Options exercisable at$0.22 per option expiring 31 October 2028100,000 Unlisted Options exercisable at $2.52per option expiring 2 December 20282,000,000 Unlisted Options exercisable at$0.5075 per option expiring 24 October 2029Indirect46,373,750 Fully Paid Ordinary Shares held byLTR Medical Pty Ltd982,143 Fully Paid Ordinary Shares held byLTR Consulting Pty Ltd4,188,000 Fully Paid Ordinary Shares held byTrexapharm Inc
Nature of changeExample: on-market trade, off-market trade, exercise of options, issueof securities under dividend reinvestment plan, participation in buy-back		Issue of 2,000,000 Unlisted Options under theEmployee Incentive Plan as approved byshareholders at the Company’s 2025 AnnualGeneral Meeting (Resolution 7)

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	Not applicable
Name of registered holder(if issued securities)	Not applicable
Date of change	Not applicable

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

No. and class of securities to which interest Not applicable related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Not applicable Interest disposed Not applicable Value/Consideration Not applicable Note: If consideration is non-cash, provide details and an estimated valuation Interest after change Not applicable

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the Not applicable trade to proceed during this period? If prior written clearance was provided, on what date was Not applicable this provided?

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3